Sat, Aug 30, 2014, 1:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • pashidev pashidev Mar 31, 2011 11:15 AM Flag

    Top reasons why OPTR will get FDA approval...

    I guess release is on Friday as per the following Analyst. How to access it?


    Canaccord Genuity Assumes Coverage on Optimer Pharmaceuticals (OPTR) at Buy; FDA Panel Expected to Weigh Favorably on Fidaxo NDA11:08 am ET 03/31/2011 - StreetInsiderCanaccord Genuity assumes coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy. PT $16.
    Canaccord analyst says, "Going into an upcoming FDA advisory committee meeting on Tuesday, we maintain our rating on OPTR given our view of high likelihood of support for the company s lead drug, fidaxomicin, for treatment of C. diff. infection. Briefing documents expected for release on Friday could support this claim, thus setting the stage for marketing approval by the May 30 PDUFA date." (Coverage has been transitioned to George Farmer)
    "Initially to be positioned in a high-risk treatment market and in vancomycinfailures, we model for a slow ramp to peak fidaxomicin sales of $250M by2016. More rapid adoption will depend largely on physician experience andaccelerated acceptance by hospital formularies."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Well, at least one analyst still thiks this will be approved:

      March 31, 2011 11:08 AM EDT

      Canaccord Genuity assumes coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy. PT $16.

      Canaccord analyst says, "Going into an upcoming FDA advisory committee meeting on Tuesday, we maintain our rating on OPTR given our view of high likelihood of support for the company’s lead drug, fidaxomicin, for treatment of C. diff. infection. Briefing documents expected for release on Friday could support this claim, thus setting the stage for marketing approval by the May 30 PDUFA date." (Coverage has been transitioned to George Farmer)




      http://www.streetinsider.com/FDA/Canaccord+Genuity+Assumes+Coverage+on+Optimer+Pharmaceuticals+(OPTR)+at+Buy%3B+FDA+Panel+Expected+to+Weigh+Favorably+on+Fidaxo+NDA/6399385.html

      • 1 Reply to lavicat2003
      • Gnerally makes sense, although one of the statement requires amplification: "Initially to be positioned in a 'high-risk' treatment market and in vancomycin
        failures,".

        Rational antibiotic usage would dictate use of this narrow spectrum antibiotic ahead of vancomicin for C-diff. Hospitals are becoming seriously concerned about vancomycin resistant MRSA -- this is a significant issue resulting from the rising use of vancomycin. Vancomycin should be saved as a last resort antibiotic for such life threatening infections.

        Whether this positioning occurs epends upon the company's marketing effectiveness but also significantly, if generic vancomycin caps are delayed so cost does not become an offsetting motivation.

 
OPTR
12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.